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Summary 
We have prospectively followed 16 Finnish Xeroderma pigmentosum (XP) patients up to 23 years.  
Seven patients were assigned by complementation analysis to the group XP-A, two patients to the XP-
C group and one patient to the XP-G group. Six of the seven  XP-A patients had the identical mutation 
(Arg228Ter).  The seventh patient has a different mutation (G283A). Further patients were assigned to 
complementation groups on the basis of their consanguinity to a XP patient with a known 
complementation group. The first sign of the disease in all the cases was severe sunburn with minimal 
sun exposure in early infancy.  However, the diagnosis was made at that time only in two cases.  The 
XP-A patients developed neurological and cognitive dysfunction already in childhood.  The 
neurological disease advanced in orderly fashion through its successive stages, finally affecting the 
whole nervous system and leading to death before the age of 40 years. Dermatological and ocular 
damage of the XP-A patients tended to be limited.  The two XP-C patients were neurologically and 
cognitively intact in spite of the mild brain atrophy in neuroimaging.  The XP-G patients had  
sensorineural hearing loss, laryngeal dystonia and peripheral neuropathy.  The XP-C patients had 
severe skin and ocular malignancies first presented at preschool age.   They also showed 
immunosuppression in cell-mediated immunity. Neurological disease appears to be associated with 
complementation group and the failure of fibroblasts to recover RNA synthesis following UV 
irradiation, but not necessarily to the severity of the dermatological symptoms, the hypersensitivity of 
fibroblasts to UVB killing, or the susceptibility of keratinocytes to UVB-induced apoptosis.   
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Introduction 
Xeroderma pigmentosum is a rare autosomal recessive disease with cutaneous, ocular and neurological 
symptoms. The basic defect is in DNA repair. Xeroderma pigmentosum was first described clinically in 
1874 by Hebra and Kaposi (Hebra and Kaposi, 1874; Kaposi, 1882) as a syndrome of sunlight 
hypersensitivity, freckles and skin cancers. De Sanctis and Caccione (1932) reported the neurological 
manifestations of the disease in 1932.  XP occurs in all races. The frequency is approximately 1: 
250,000 in Europe and USA, in Japan it is higher, 1: 30,000 (Kraemer et al., 1987). 
 XP patients have been assigned into eight complementation groups.  Seven of these (XP-A to XP-G) 
are associated with defects in nucleotide excision repair (NER), the process in which bulky lesions 
including UV photoproducts are removed from the DNA. In the eighth form (XP variant form, XP-V) 
the defect is in translesion synthesis, the ability to replicate DNA templates carrying unrepaired DNA 
damage. All the genes and chromosomal locations associated with the complementation groups have 
been identified (Wattendorf and Kraemer, 2005). XP-A and XP-C are the most common 
complementation groups in Europe. In general, XP-A patients have the most profound DNA repair 
defect with minimal or no repair activity and in this group neurological symptoms are common.  In XP-
C the skin problems are severe, but neurological symptoms are rare.  Neurological, dermatological and 
ocular symptoms may vary from mild to severe in two persons with the same complementation group, 
or even sibs (Kraemer and Slor, 1985).  
The disease typically starts with skin symptoms.  Progressive neurological manifestations, including 
cognitive deterioration, occur in about 20-30% of the patients, more commonly in groups XP-A, D and 
G.  Ocular symptoms are seen in nearly 80 % of XP patients starting early in childhood with 
photophobia and conjunctivitis. Later malignant tumours may also involve the eyes. 
In the present study, we have prospectively followed neurological abnormalities and other clinical 
manifestations in 16 Finnish XP-patients for up to 23 years. Neuropathology of one of our patients 
(XP-A) has been published earlier (Roytta and Anttinen, 1986).   
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Patients and methods 
We have prospectively followed the clinical course of 16 Finnish XP patients from 2 to 23 years. This 
is a hospital based patient study from different departments of dermatology and neurology in Finland. 
The follow up started in 1981 and so far 16 patients have been studied.  The patients were given a case 
number in the order they were included into the study.   The examinations were carried out in Turku 
University Central Hospital.  Most patients were fully examined twice (1982, and 1988 or 1998) as in-
patients and more often followed up in the dermatological and neurological out-patient clinics. The first 
clinical examination took place between the age of one and 36 years.  Each subject or his/her guardian 
was fully informed of the procedures and gave a written informed consent before the entry into the 
study, which was approved by the local Ethics Committee. 
The patients have been examined clinically by a neurologist, dermatologist and neuro-ophthalmologist. 
In addition, a computed tomography of the brain or /and a brain MRI (1,5 Tesla) were performed where 
applicable.  The otological examination included an audiogram.  Standard EEG-recordings were 
obtained and electroneuromyography (ENMG) examination and interpretation were made by the 
clinical neurophysiologist.  Neuropsychological examinations were carried out to measure verbal, 
visuomotor and memory performances.    The overall level of performance was evaluated using three 
verbal (Arithmetic, Similarities and Digit span) and four visuomotor (Digit symbol, Picture completion, 
Block design and Object assembly) subtests of the WAIS (Wechsler 1955). Digit span forwards and 
backwards served as a measure of working memory.   
Since the T cell-mediated tumor immunity is a major defence strategy against neoplasms, we studied 
the cell-mediated immune reactivity in XP patients using the contact hypersensitivity (CHS) model 
(Cooper et al., 1992). 
Skin punch biopsies were obtained from ten cases and fibroblast cultures established according to 
standard procedures and ethical guidelines.  For five cases, it  was also possible to establish short-term 
keratinocyte cultures (Petit-Frère et al.,2000). Cellular DNA repair assays were performed in the 
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former MRC Cell Mutation Unit (now the Genome Damage and Stability Centre), University of 
Sussex, Brighton and in the Erasmus University. UVB survival (Arlett et al., 1992), UVC survival 
(Jaspers et al., 2002), unscheduled DNA synthesis (Lehmann and Stevens, 1980) and (Vermeulen et al., 
1991) and long-term inhibition of RNA synthesis in fibroblasts (Lehmann et al., 1993) were determined 
as described previously. Complementation analysis to identify the affected gene was performed in The 
Medical Genetic Cluster, Erasmus University in Rotterdam as described previously (Vermeulen et al., 
1991). Apoptosis and cytokine release and expression in keratinocytes have been reported previously 
(Petit-Frère et al., 2000). The mutations in the XP-A patients were determined using RT-PCR from 
total RNA and direct sequencing of the amplified cDNA. 
The XP-G patients were examined only clinically in the year 2002.  One of them had been diagnosed 
prenatally. 
 
Results  
Complementation analysis 
Complementation analysis has been carried out in nine cases since 1996. At that time five patients were 
already deceased.  Seven of those analyzed turned out to be XP-A (definite XP-A), two patients were 
XP-C and one, earlier, prenatally diagnosed, XP-G (Table 1). Cases 1 and 3 were sisters of Case 11, 
whose complementation group was XP-A.  The healthy mother of XP-A case 14 is a cousin of case 9.  
The XP-G patients are brothers. Complementation analysis was not carried out for cases 2 and 4. The 
mutations in the XP-A patients were identified by sequence analysis. Cases 5, 7, 11-14 had the 
identical mutation a homozygous truncation mutation at codon 228 (Arg228Ter) in the last exon of the 
XPA protein. Case 6  has the homozygous mutation G283A, changing the last base of exon 2. This 
results in the majority of the mRNA being aberrantly spliced with deletion of one or more of the exons 
downstream of exon 2.(Table 6) 
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Dermatological signs 
According to the clinical records, the first clinical sign in all the cases was severe sunburn with 
blistering or persistent erythema after minimal sun exposure, like sleeping early in spring in a shaded 
place in a pram. This occurred in all the cases (XP-A, XP-C, XP-G) before the age of one, but led to 
diagnosis in only two of the cases (9 and 14). Later the sensitivity to sunburn diminished in some of the 
patients. In all the patients except case 14 freckling of the face was evident at the age of two years.    
At clinical examination, poikiloderma with hyper- and hypopigmentation and skin atrophy was seen in 
all the patients except case 14, who has been carefully protected from UV-exposure.  Absence of 
pigmentary changes was evident on the areas protected from sunlight (Fig.1). 
The first skin malignancies were diagnosed in the XP-C patients at preschool age. As a total, both of 
them have had over hundred non-melanoma skin cancers (NMSC). In the XP-A patients the 
malignancies occurred later, and half of the XP-A patients have had no skin malignancies.  One of the 
XP-A patients has had a cutaneous malignant melanoma (CMM) and one of the XP-C cases has had 
several CMMs.  The XP-G patients have had no skin malignancies.  
For seven cases (5 XP-A, 2 XP-C) the basal cutaneous cell-mediated immune reactivity to  
diphenylcyclopropenone (DPCP) was investigated using a DPCP sensitization dose which sensitizes 
every healthy control person. A primary allergic response (PAR) is an indicator of aroused 
sensitization. It is a spontaneous flare of contact hypersensitivity at the site of allergen application 1-2 
weeks after the epicutaneous application of the allergen. Later the sensitized individuals react when 
challenged to small amounts of the same allergen. Three of the patients showed basic 
immunosuppression in cell-mediated immunity, they were not sensitized to DPCP (Table 2, both the 
XP-C cases and XP-A Case 6). Basic immunosuppression of cell-mediated immunity is likely to 
contribute to the development of skin malignancies especially in XP-C patients   
Ophthalmological signs 
Eleven out of the thirteen patients who underwent ophthalmological examination had eye symptoms. 
Common complaints were photophobia, excessive weeping, blepharospasm and/or decreased vision.  
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Seven patients had irritative conjunctivitis and nine pterygia.   
Four patients had nodular tumours in their eye lids. One patient had limbal premalignant dysplasia. 
Symblepharon (Fig.2) was observed in six patients; two of these patients had experienced several 
oculoplastic surgeries. 
Keratopathy, scarring, exposure keratitis and premalignant dysplasia were corneal findings in five 
patients and progressed to permanently severe visual loss in two eyes despite oculoplastic surgery and 
penetrating keratoplasty.  Examples of the ophthalmological findings are illustrated in Fig.2. 
Eye examinations did not reveal neuro-ophthalmological pathology. 
The visual prognosis was poor in two patients with XP-C. One patient became permanently blind due 
to the malignant eye lid, conjunctival and corneal changes.  The other patient lost the right eye, because 
of severe symblepharon and corneal ulcerations.                             
Neurological signs 
The clinical course of the disease in definite and probable XP-As is presented in Tables 1 and 3 With 
one exception (Case 6, late juvenile onset type) the neurological manifestations and the clinical course 
of the disease are similar. All these patients have short stature and their heads are microcephalic. 
Secondary sexual characteristics are poorly developed. Case 6 has given birth to two sons, however. 
The patients had normal early development until the age of two years.  The first neurological symptoms 
appeared before the age of 8 years. According to the development history given by the parents the first 
symptom was mild cognitive impairment in all the cases.  The patients usually started school normally. 
However they did not manage a normal school and had to continue approximately within three years in 
special schools for mentally retarded children.  All the patients showed slight to severe diffuse 
encephalopathy in EEG.  
The next symptoms were cerebellar, predominantly presenting as dysarthria without swallowing 
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problems.  Difficulties in speaking were followed by disturbances in balance. The neurological signs 
were ataxia of the legs with milder ataxia of the upper limbs. Cerebellar symptoms usually occurred 
between the age of 4-16 years. Later, progressive difficulties in walking are explained also by 
concurrent neuropathy.  The clinical examination revealed areflexia and neuropathy was confirmed by 
ENMG, which showed moderate to marked axonal sensory motor neuropathy. Neuropathy was usually 
first seen in the second decade, becoming more severe in the third decade. (Table 3) 
In addition to cognitive impairment, the patients also exhibited an unusual mental symptom occurring 
as increased sensitivity and tendency to weep and to be frightened.  This symptom was common (8 / 11 
adults). Six out of the 11 adult patients had developed choreoathetoid type involuntary movements, 
predominantly in the upper limbs, starting in early adulthood.   
Sensorineural deafness in audiogram was seen in all cases, except Case 6.  
Corticospinal involvement was usually observed in the third decade, slowly progressing to spastic 
tetraplegia some years before the death.  At that time the cognitive impairment was severe and the 
patients needed help in all daily activities. They had severe difficulties in swallowing and walking, 
needed a wheelchair and were bedridden within a couple of years. 
Seven patients have died, all severely neurologically affected.  The median age at death was 33 years 
(29-40yr).  The cause of the death was pneumonia in all the cases. 
The XP-C patients went through all the neurological examinations with normal findings.  
The XP-G patients were examined once at the ages of  22 and 34 years.  They are remarkably short in 
stature and have a bird like face (Fig.3). Both of them have severe laryngeal dystonia. They graduated 
from high school and are employed. Case 16 has cerebral palsy, spastic diplegia. Both cases have 
sensorineural hearing loss. Neurological examination revealed areflexia suggesting polyneuropathy.   
No ENMG examinations were carried out on these patients.  Otherwise the neurological examination 
was normal. 
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Neuropsychological findings 
Altogether 11 patients completed cognitive testing by a neuropsychologist.  Four of the patients (2 XP-
A and 2 XP-C patients) were examined twice within 15 years.   
The two XP-C patients performed normally on all tasks both at initial examination and at follow-up 15 
years later.  
 All but one (the late juvenile onset type, case 6) of the XP-A patients showed moderate to severe 
overall cognitive impairment (Table 4). The patient with late juvenile onset type performed otherwise 
normally at baseline except mild working memory difficulties, and showed further impairment in 
working memory and arithmetic but preserved other skills at follow-up 15 years later. Most XP-A 
patients had problems in speech production, not only due to dysarthria but also verbal processing 
deficits. There were no specific cognitive impairment profiles, but many patients could perform at a 
relatively good level in some cognitive domains, most often in semantic knowledge, in spite of overall 
impairment. (Table 4) 
Neuroimaging 
Nine XP-A patients and two XP-C patients were studied.    Six patients (4 XP-A and 2 X-PC) were 
studied by 1.5 Tesla MRI, in case 6 the imaging was performed twice. At least T2-and T1-weighted 
images were obtained in all the cases.  Six of the patients were studied by CT, in case 5 CT was 
performed two times.  The summary of the findings is shown in Table 5.  
Calvarial thickening was seen in 9 XP-A cases, in all of them the thickening was most prominent in 
frontal bones, the occipital bone was thickened only in 2 cases.  Additionally, thickening of sphenoidal 
and temporal bones was observed in 3 cases. 
Brain atrophy was demonstrated in all 11 studied patients, including the XP-C patients. In both the XP-
C patients and case 6 (late juvenile onset type) general atrophy was mild while in other 8 patients the 
atrophy was moderate or severe.  The atrophy was generally symmetrical and covered all lobes, deep 
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grey and white matter structures, brainstem and cerebellum. Of the patients with cognitive and memory 
impairment, general and hippocampal atrophy was light in case 6, and in the other cases moderate or 
severe. 
In six patients including the XP-C cases white matter T2-hyperintensities were demonstrated with MRI.  
In 3 of them only slight periventricular changes and a hyperintense band in the capsula externa were 
detected. In 2 cases more advanced white matter pathology was seen; in cerebrum only U-fibres 
showed normal signal intensity.  In one patient also superficial U-fibres were T2-hyperintense. In this 
case also hypointensity of putamen and nucleus caudatus was demonstrated on both sides Fig. 4. 
Cellular studies 
The experiments on fibroblast cultures are summarised in Table 6.  Sensitivity to UVB killing was 
determined for four XP-As (Cases 5, 6, 12 and 13) and two XP-Cs (Cases 8 and 10).  A Westinghouse 
FS20 broad spectrum UVB lamp was used.  Case 6 is slightly more sensitive, but the remaining three 
XP-As and the two XP-Cs show similar sensitivity.  Sensitivity to UVC killing varied from 5 to 11 
times the normal. 
Unscheduled DNA synthesis (an indicator of excision repair) following 5 J/m2 UVC irradiation was 
measured for six XP-As (all save case 14) and the two XP-Cs.   XP-A cases 12 and 13, and the XP-C 
cases appeared to show greater residual repair. 
Persistence of inhibition of RNA synthesis 24 h after the irradiation with  5 J/m² of UVC was measured 
for two XP-As (Cases 6 and 12) and one XP-C (Case 8).  RNA synthesis was inhibited in the two XP-
As, but had recovered normally in the XP-C. RNA synthesis was inhibited 16 h after the irradiation 
with 10 J/m² in the cases 14 and 15.  
It proved possible to generate short-term keratinocyte cultures from five of the biopsies (XP-A cases 
5,6 and 12; XP-C cases 8 and 10) and to perform limited studies on UVB-induced apoptosis and 
cytokine release.  These data have been reported previously (Petit-Frere et al, 2000), and are 
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summarised in Table 7. All three XP-A cases showed substantially greater apoptosis that the normal 
keratinocyte controls.  However, the two XP-C cases gave different responses.  XP-C case 8 gave an 
XP-A-like apoptotic response, whereas XP-C case 10 showed the intermediate level of apoptosis which 
might have been anticipated (Ljungman and Zhang, 1996).   Only for the three XP-A cases could the 
keratinocytes be tested for sensitivity to UVB-induced cytokine release.   All showed increased release.  
The unirradiated cultures also showed increased release of interleukin-6, but not tumour necrosis 
factor- 
                                                  
Discussion 
We identified patients in three different XP groups (XP-A, XP-C and XP-G) in Finland. In most XP 
patients the features can be attributed to defects in NER of DNA damage. There are two sub-pathways 
of NER, transcription-coupled repair (TCR), in which damage in the transcribed strand of active genes 
is rapidly repaired, and global genome repair (GGR), a slower process for removing damage from the 
bulk of the genome. XP-A and XP-G patients are defective in both these processes, whereas XP-C 
patients are deficient in GGR but proficient in TCR.  
XP group A is the most frequently occurring type worldwide, as is also the case in Finland.  The 
neurological abnormalities in most of our patients suggest that our XP-A patients are early juvenile 
onset type, resembling the clinical features originally reported by De Sanctis and Caccione. These 
patients are clinically (neurological, cognitive, ocular and dermatological manifestations) quite similar 
in different ages, and indeed we found that they all had the same truncating mutation in exon 6.  This 
mutation arg228ter, found in 6 out of 7 of our XP-A patients has been reported previously in several 
XP-A patients from Japan and Tunisia (see http://xpmutations.org/mutations.html).  These cases were 
considered to show somewhat milder clinical manifestations than those of patients  with a mutation 
affecting splicing of intron 3 which would be essentially a null mutation resulting in no functional 
protein (Nishigori et al., 1993; Maeda et al., 1995).  
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Case 6 is a late juvenile onset type showing only mild signs of cognitive impairment.. The mutation in 
this patient generates aberrantly spliced mRNA, which would not be expected to produce any 
functional protein. However we previously reported an XP-A case with no neurological abnormalities 
despite having barely detectable NER. This patient also had a splicing abnormality, but we were able to 
detect a very small amount of normal splicing to generate minimal levels of normal protein. It appeared 
that this small amount of normal protein was sufficient to allay all the neurological problems normally 
associated with XP-A defects (Sidwell et al., 2006). We suspect that the mild features of  case 6 are 
similarly likely to result from a small amount of normal splicing of the mRNA. This patient showed 
immunosuppression in the cell-mediated immunity like the XP-C patients, however, she was not 
especially prone to skin malignancies (Table 2). As found in several other studies, our XP-C patients 
did not show any significant neurological abnormalities, indicating the importance of TCR in 
protection from lesions that might generate neurological damage. 
All the patients demonstrated acute sun sensitivity in the first year of life. However, this led to 
diagnosis in only two of the cases. Despite the numerous skin malignancies, even melanomas, the XP-
C patients have survived and some of the tumours seem to have self-healed. The phenomenon of 
spontaneous regression of primary and secondary melanomas in a XP-C patient has been described 
previously (Anstey et al., 1991) and it was proposed that the natural killer cell function led to the 
regression of the melanomas. The immunological status of XP needs further studies.  
No diagnosis of internal malignancies was done in our XP patients during this follow up and the cause 
of death was pneumonia in all our patients. However, in the literature (Di Giovanna et al, 1998, 
Kraemer et al., 1987, Kraemer et al., 1994) there is a suggestion of an approximate ten- to twenty- fold 
increase in internal malignancies.  
The eye findings of our patients were similar to those reported earlier (Dollfus et al., 2003, Goyal et al., 
1994).  Two patients with XP-C became permanently visually handicapped.  The exposure to excessive 
sunlight perhaps caused the limbal premalignant dysplasia in a young man with XP-A working as a 
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gardener in a cemetery. 
Neurological affision, including low intelligence, spasticity, ataxia, areflexia and hearing loss, is known 
to be associated with XP in about 18 per cent of  cases published up to 1982 (Kraemer et al, 1987).  In 
Japanese patients with XP-A over 7 years of age sensorineural deafness, nystagmus, dysarthria, ataxia 
and hyporeflexia were frequently observed (Mimaki et al., 1986). Both of above studies were cross-
sectional  and included mostly patients at early childhood.  Because of a long follow-up period, we 
have been able to describe more precisely the natural course of this relentless disease.  According to a 
previous knowledge we observed the most severe neurological disease in patients with XP-A ( 
Thielmann et al., 1991, Rapin et al., 2000). However, we also noted neurological signs such as 
sensorineural hearing loss, neuropathy and laryngeal dystonia in XP-G patients thought to be free of 
neurological illness (Rapin et al., 2000). In XP-A patients, there is a certain order in which the 
neurological symptoms seem to appear.  The neurological symptoms probably start slowly at about the 
age of two and are clearly seen at the age of 4-5 years manifesting cognitive and cerebellar signs. 
Afterwards the neurological symptoms slowly progress, finally leading to a premature death while 
affecting the whole nervous system as also seen in our neuropathological study of case 1 (Roytta and 
Anttinen, 1986).  
The XP-A patients, except the late juvenile onset type, showed more often than described earlier 
moderate to severe progressing intellectual deterioration, but no specific impairment profiles were 
found.  
Neuroimaging (CT and MRI) correlated with the severity of the neurological and cognitive impairment 
in XP-A patients. Surprisingly the XP-C patients, though neurologically and cognitively asymptomatic, 
had minimal general atrophy, slight cerebellar atrophy and white matter signal changes probably 
reflecting degeneration of neural tissue.  
UV radiation penetrates only into the skin.  Therefore the cause of the neurological disease cannot be 
the UV photoproducts that generate the clinical spectrum of disorders presented by the skin cancers and 
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corneal damage.  A likely cause of the neurological problems is the accumulation of unrepaired 
oxidative DNA lesions in the brain, which result in progressive neuronal death. Suggested candidate 
lesions are cyclopurines (Kuraoka et al., 2000 Brooks  2007). However compared to the skin, the CNS 
is a much less tractable system for biochemical and cell biological studies, and our understanding of the 
origin of the neurological abnormalities in XP is still in its infancy. Since nowadays patients that are 
diagnosed early and well protected from sunlight suffer minimal skin problems and are living longer 
than in the past, neurological problems associated with XP are becoming of relatively greater 
importance in XP families and should be the focus of future research. 
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Table 1: Basic characteristics and summary of clinical symptoms 
 
Patient Cell 
Designation 
Comple-
mentation group 
Onset of 
neurological 
symptoms 
Ocular 
symptoms 
First  
sunburn 
Onset  and number of 
skin malignances 
 
 
Case 5 
 
 
XP5TUF 
 
A 
 
8 yr 
 
+ 
 
6 mo 
 
None 
 
Case 6 
 
 
XP1TUF 
 
A 
 
21 yr 
 
+ 
 
3 weeks 
 
34yr 
BCC x 1 
 
Case 7 
 
 
XP6TUF 
 
A 
 
4 yr 
 
+ 
 
11 mo 
  
In adolescence 
NMSC > 10 
CMM x 1 
 
Case 11 
 
 
XP8TUF 
 
A 
 
7 yr 
 
++ 
 
12 mo 
 
12yr 
BCC x 10 
 
Case 12 
 
 
XP3TUF 
 
A 
 
4 yr 
 
+ 
 
4 mo 
 
11yr 
BCC x 10 
 
Case 13 
 
 
XP7TUF 
 
A 
 
3 yr 
 
+ 
 
3 mo 
 
None 
 
Case 14 
 
 
XP9TUF 
 
A 
 
None 
 
None 
 
2,5 mo 
 
None 
 
Case 1 
 
 
Nd 
 
A* 
 
5 yr 
 
None 
 
6 mo 
 
14 yr 
BCC x 2 
 
Case 2 
 
 
Nd 
 
Unassigned$ 
 
4 yr 
 
+ 
 
3 mo 
 
None 
 
Case 3 
 
 
Nd 
 
A* 
 
4 yr 
 
+ 
 
2 mo 
 
None 
 
Case 4 
 
 
Nd 
 
Unassigned$ 
 
6 yr 
 
ND 
 
10 mo 
 
23 yr 
BCC x 2 
 
Case 9 
 
 
Nd 
 
A* 
 
4 yr 
 
+ 
 
8 mo 
 
None 
 
Case 8 
 
 
XP2TUF 
 
C 
 
None 
 
+++ 
 
10 mo 
 
6yr 
NMSC > 100 
CMM x 8 
 
 
Case 10 
 
 
XP4TUF 
 
C 
 
None 
 
+++ 
 
8 mo 
 
4yr 
NMSC > 100 
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Case 15 
 
XP1HEF 
 
G 
 
NA 
 
ND 
 
4 mo 
 
None 
 
Case 16 
 
Nd 
 
G* 
 
NA 
 
ND 
 
8 mo 
 
None 
 
Table 1 continued.  
A* = XP-A, based on consanguinity with assigned cases 
G* = XP-G, based on consanguinity with assigned case 
$These patients were not assigned to a complementation group.  
Nd, not done 
NA, not applicable 
ND, not determined 
BCC=basal cell carcinoma 
CMM=cutaneous malignant melanoma 
NMSC=nonmelanoma skin cancer 
Cell designation is given in the laboratory and describes the origin of the cell cultures, TUF means 
Turku, Finland and HEF means Helsinki, Finland. The number is the order the cell cultures were 
performed.  
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Table 2: Sensitization with 40g Diphenylcyclopropenone  (DPCP): primary allergic response and 
response to different doses of the allergen in challenge (Nd = not done) 
 
Patient 
Cell 
Designation 
Comple-
mentation 
group 
Primary 
allergic 
response 
6.4 g g g g g 
 
Case 5 
 
XP5TUF A Yes Nd ++ ++ ++ + 
 
Case 6 
 
XP1TUF A No - - - - - 
 
Case 7 
 
XP6TUF A Yes Nd Nd Nd Nd Nd 
 
Case 12 
 
XP3TUF A Yes Nd +++ +++ ++ + 
 
Case 13 
 
XP7TUF A Yes Nd Nd Nd ++ + 
 
Case 8 
 
XP2TUF C No - - - - - 
 
Case 10 
 
XP4TUF C No - - - - - 
 
  
Table 3.  Age (yrs) at onset of neurological abnormalities  
Definite  XP-A 
Patient/ 
birth  
year 
Any  
neurological 
symptom 
Cognitive  
dysfunction 
 
Cerebellar  
involvement 
 
Basal  
ganglia  
involvement 
 
Mental  
symptoms 
Hearing* 
(audiogram) 
Peripheral  
neuropathy* 
(ENMG) 
Corticospinal  
involvement* 
Wheelchair
/  
bedridden  
Age of 
 death 
Case 5 
1961 
8 8 15 20 15 20 
SNHL 
20 
++ 
20 
+ 
27/33 38 
Case 6 
1962 
21 21 33 33 33 34 
Normal 
34 
++ 
- - NA 
Case 7 
1962 
4 4 16 - - 36 
SNHL 
36 
+++ 
36 
++ 
38/40 NA 
Case 11 
1968 
7 7 8 30 10 Nd Nd 24 
+ 
30/30 33 
Case 12 
1970 
4 4 4 - - 28 
SNHL 
28 
+++ 
28 
++ 
- NA 
Case 13 
1981 
3 3 5 - - 18 
SNHL 
18 
+ 
18 
- 
- NA 
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Table 3.  Age (yrs) at onset of neurological abnormalities (continued) 
 
Probable  XP-A and unassigned cases 
Patient/ 
birth 
year 
Any 
neurological  
symptom 
Cognitive  
dysfunction 
 
Cerebellar  
involvement 
 
Basal  
ganglia  
involvement 
 
Mental  
symptoms 
Hearing*  
(audiogram) 
Peripheral 
neuropathy
* 
( ENMG) 
Corticospinal  
involvement* 
Wheelchair
/ 
Bedridden 
 
Age 
of 
death 
Case 1 
1949 
5 5 5 - 11 Nd 32 
+++ 
32 
+++ 
25/28 32 
Case 2 
1952 
4 7 4 18 18 30 
SNHL 
30 
+++ 
30 
++ 
32/- 40 
Case 3 
1960 
4 4 10 17 17 22 
SNHL 
22 
++ 
22 
++ 
26/28 32 
Case 4 
1960 
6 6 12 26 7 Nd 26 
++ 
22 
++ 
26/- 29 
Case 9 
1964 
4 4 4 - 17 17 
SNHL 
17 
++ 
17 
- 
NA 35 
 
basal ganglia involment =  involuntary movements 
SNHL = sensorineural hearing loss 
-  no symptoms  
* shows the age when examined and severity of symptoms( - none, + mild, ++ moderate and +++ 
severe)  
Nd, not done 
NA, not applicable  
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Table 4. Neuropsychological findings 
 
Definite  XP-A 
Patient Age (yr) 
when 
examined 
Impairment of intellectual function 
 Degree of  overall 
impairment 
Relatively preserved 
cognitive 
domains 
Most affected cognitive 
domains 
Case 5 20 Moderate to severe 
V IQ 70, PIQ 42 
WM, semantic knowledge Numerical reasoning, 
visuomotor  skills, speech 
production limited 
Case 6 
 
19 None to mild 
VIQ 93, PIQ 100 
Verbal skills, semantic 
knowledge, 
visuomotor skills 
Verbal WM 
 
34 None to mild 
VIQ 86, PIQ 107 
Verbal skills, semantic 
knowledge, 
visuomotor skills 
Verbal WM 
Numerical reasoning 
Case 7 36 Severe 
VIQ 44, PIQ 37 
 WM, visuomotor skills 
Speech production very 
limited 
Case 11 30 Severe   
Case 12 28 Severe 
VIQ 47, PIQ 43 
Visuoconstructive skills WM, verbal skills 
Case 13 18 Severe 
VIQ 49 PIQ - 
 WM 
Verbal and visuomotor skills 
Case 14  Not done   
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Table 4. Neuropsychological findings (continued) 
 
Probable  XP-A and unassigned cases 
Patient Age (yr) 
when 
examined 
Impairment of intellectual function 
 Degree of overall  
impairment 
Relatively preserved 
cognitive domains 
Most affected cognitive 
domains 
Case 1 32 Severe 
VIQ -,  PIQ 30 
  
Case 2 
 
30 Severe 
VIQ 58, PIQ 37 
WM 
Semantic knowledge 
Visuomotor skills 
Speech production limited 
Case 3 20 Severe 
VIQ 45, PIQ 40 
Selective visuoconstructive 
performance 
WM, verbal skills 
Speech production very 
limited 
Case 4§ 
 
13 Moderate   
26 Severe   
Case 9 17 Moderate 
VIQ 76, PIQ 56 
WM, semantic knowledge 
Speech production 
Numerical reasoning 
 
§=psychological examination/ behavioural  evaluation 
VIQ = verbal IQ 
PIQ = performance IQ 
WM = working memory 
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Table 5. Neuroradiological findings 
 
Definite  XP-A 
 
Patient 
Age(yr) 
when 
examined 
Brain CT/MRI 
Case 5 
 20 CT: Moderate cerebral, slight brainstem and cerebellar atrophy 
34 CT: Moderate general atrophy 
Case 6 
 
21 CT: Normal 
34 
MRI: Calvarial hyperostosis, moderate general brain atrophy, moderate cerebellar and 
hippocampal atrophy, white matter T2-hyperintensity excluding U-fibers 
41 
MRI: Increased calvarial hyperostosis, moderate general brain atrophy, severe atrophy 
in corpus callosum, basal ganglia and cerebellum; white matter hyperintensity slightly 
increased 
Case 7 36 
MRI: Calvarial hyperostosis; moderate general atrophy, severe atrophy in frontal and 
parietal lobes and corpus callosum, moderate hippocampal atrophy; general white 
matter T2-hyperintensity including U-fibers, basal ganglia T2-hypointensity 
Case 11  Nd 
Case 12 27 
MRI: Calvarial hyperostosis, moderate general brain atrophy, moderate hippocampal 
and cerebellar atrophy; white matter T2-hyperintensity excluding U-fibers  
Case 13 17 
MRI: Hyperostosis in sphenoidal and temporal bones; slight general brain atrophy, 
slight hippocampal atrophy, moderate callosal atrophy; periventicular T2-
hyperintensity 
Case 14  Nd 
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Table 5. Neuroradiological findings (continued) 
Probable  XP-A and unassigned cases 
 
Patient 
Age(yr) 
when 
examined 
Brain CT/MRI 
Case 1 32 CT: Moderate central and cortical atrophy, prominent thickening of skull 
Case 2 30 CT: Moderate central and cortical atrophy 
Case 3 20 CT: Calvarial thickening, generalized cortical and central atrophy 
Case 4  Nd 
Case 9 17 CT: Moderate central atrophy, slight cortical and cerebellar atrophy 
 
XP-C 
 
Patient 
Age(yr) 
when 
examined 
Brain CT/MRI 
Case 8 33 
MRI: Minimal lobar cerebellar and brain stem atrophy, no hippocampal atrophy; 
slight periventricular and subinsular T2-hyperintensity 
Case 10 32 
MRI: Minimal general atrophy; slight cerebellar atrophy, minimal hippocampal 
atrophy; periventricular and subinsular T2-hyperintensity 
 
 
Nd, not done 
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Table 6: Fibroblast data for individual cases 
 
Patient 
Cell 
Designation 
Comple-
mentation 
group and 
mutation 
Cell survival 
(sensitivity x normal)
a
 
Unscheduled DNA 
synthesis 
after UVC 
b
  
(% vs normals)   
Inhibition of 
RNA synthesis 
after UVC 
c
  
(% vs 
normals) 
UVB UVC 
 
Case 5 
 
 
XP5TUF 
 
A 
Arg228Ter 
11 x 7.5 x 0 ,  < 3  
 
Case 6 
 
 
XP1TUF 
 
A  
G283A 
22 x 11 x 0 , < 3 14.3 
 
Case 7 
 
 
XP6TUF 
 
A 
Arg228Ter 
 10 x 2.4 ,   < 3  
 
Case 11 
 
 
XP8TUF 
 
A 
Arg228Ter 
 9 x 0 , < 3  
 
Case 12 
 
 
XP3TUF 
 
A 
Arg228Ter 
14 x 10 x 27.0,   < 5 20.4 
 
Case 13 
 
 
XP7TUF 
 
A 
Arg228Ter 
11 x 6.2 x 23.2,  20-25  
 
Case 14 
 
 
XP9TUF 
 
A 
Arg228Ter 
  < 3 < 10 
 
Case 8 
 
 
XP2TUF 
 
C 
Nd 
9 x 5.0 x 17.5 , 10-15 89.2 
 
Case 10 
 
 
XP4TUF 
 
C 
Nd 
11 x 5.5 x 13.1,  15-20  
Case 15 XP1HEF 
G 
Nd 
 9 x < 3 < 5 
Fibroblast 
controls 
1BR 
48BR 
C5RO 
normal - - - - 
Notes: (a) Ratios of slopes of semilog survival plots (Do or D10); (b) after doses of 5 and/or 16 J/m2, 
respectively; (c) 24h after 5 J/m2 or 16h after 10 J/m2 
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Table 7: Available keratinocyte data (summary of data presented in Petit-Frere et al, 2000) 
 
Patient 
Cell 
Design-
ation 
Comple-
mentation 
group 
% apoptosis 
at 150Jm-2 
UVB 
24h IL6 
release 
(pg/ml) at 
0 Jm-2 
24h IL6 
release 
(pg/ml) at 
100 Jm-2 
24h TNF 
mRNA 
100 Jm-2 
normalised 
vs 
MC  0 Jm-2 
24h TNF 
release 
(pg/ml) at 
100 Jm-2 
 
Case 5 
 
XP5TUF A 24.1% 3125 6905 5.60 294.4 
 
Case 6 
 
XP1TUF A 28.0% 1701 2483 87.2 19.4 
 
Case 12 
 
XP3TUF A 22.6% 9826 10785 2.15 149.4 
 
Case 8 
 
XP2TUF C 20.7% - - - - 
 
Case 10 
 
XP4TUF C 8.3% - - - - 
Keratino-
cyte 
control 
TE normal 5.2% - - - - 
Keratino-
cyte 
control 
WW normal 1.8% - - - - 
Keratino-
cyte 
control 
MC normal - 672 849 - 0 
Keratino-
cyte 
control 
MM normal - 950 1076 1.37 0.1 
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Legends for the figures 
Figure 1. 
XP-C patient, absence of pigmentary changes is evident on the areas protected from sunlight. 
Figure 2. 
Ophthalmological findings in XP. Upper left: Pterygium. Upper right: Corneal clouding and 
conjunctival hyperemia. Bottom: Symblepharon and corneal clouding. 
Figure 3. 
XP-G patient 
Figure 4. 
White matter signal changes and atrophy in MRI of an XP-A patient. 
 
